Showing results (1-10 of 24) with videos related to

Sort By:
Pageof 3
Anticancer Research|September 3, 2021
The Real-world Outcomes of Patients With Advanced Invasive Lobular Carcinoma of the Breast Compared With Invasive Ductal Carcinoma: A Review at a Single InstitutionJunichiro Watanabe, Shogo Nakamoto, Takashi Sugino
BMC Cancer|January 4, 2022
Eribulin improved the overall survival from the initiation of first-line chemotherapy for HER2-negative advanced breast cancer: a multicenter retrospective studyShogo Nakamoto, Junichiro Watanabe, Shoichiro Ohtani, et al.
Scientific Reports|November 3, 2021
Shorter duration of first-line chemotherapy reflects poorer outcomes in patients with HER2-negative advanced breast cancer: a multicenter retrospective studyShogo Nakamoto, Junichiro Watanabe, Shoichiro Ohtani, et al.
Anticancer Research|June 4, 2021
Dynamic Changes in Absolute Lymphocyte Counts During Eribulin Therapy Are Associated With Survival BenefitShogo Nakamoto, Masahiko Ikeda, Shinichiro Kubo, et al.
In Vivo (Athens, Greece)|November 4, 2020
De-escalated Therapy Omitting Anthracyclines for Stage I HER2-positive Breast Cancer: A Retrospective Observational StudyShogo Nakamoto, Masahiko Ikeda, Shinichiro Kubo, et al.
In Vivo (Athens, Greece)|May 2, 2020
Bevacizumab as First-line Treatment for HER2-negative Advanced Breast Cancer: Paclitaxel plus Bevacizumab Versus Other ChemotherapyShogo Nakamoto, Junichiro Watanabe, Shoichiro Ohtani, et al.
Cancer Diagnosis & Prognosis|April 11, 2022
The Systemic Immune Markers at Diagnosis Can Predict the Survival Benefit in Advanced Breast CancerShogo Nakamoto, Masahiko Ikeda, Shinichiro Kubo, et al.
Cancer Diagnosis & Prognosis|April 11, 2022
Prognostic Value of Lymphocyte-to-Monocyte Ratio for Japanese Patients With Differentiated Thyroid Cancer Treated With Sorafenib TherapyShogo Nakamoto, Masahiko Ikeda, Shinichiro Kubo, et al.
BMJ Case Reports|April 22, 2025
Double heterozygosity for BRCA1 and BRCA2 in breast cancer: considerations in surveillance and cancer risk managementNonoko Wakaki, Tatsunori Shimoi, Shogo Nakamoto, et al.
Scientific Reports|March 19, 2021
Systemic immunity markers associated with lymphocytes predict the survival benefit from paclitaxel plus bevacizumab in HER2 negative advanced breast cancerShogo Nakamoto, Masahiko Ikeda, Shinichiro Kubo, et al.
Pageof 3